(CUTR) Cutera - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2321091082
CUTR: Vascular Treatments, Skin Resurfacing, Hair Removal, Fat Reduction, Acne Treatment
Cutera, Inc. (NASDAQ:CUTR) is a global leader in aesthetic and dermatological solutions, offering a comprehensive suite of energy-based devices and skincare products for medical professionals. The company specializes in developing and marketing advanced technologies that address a wide range of aesthetic concerns, including acne, skin resurfacing, body contouring, hair removal, and tattoo removal. Its product portfolio includes AviClear, a groundbreaking laser treatment for inflammatory acne; Secret PRO, a dual-action device combining fractional CO2 and RF microneedling for skin revitalization; and truFlex, a bio-electrical stimulation system designed for muscle toning and contouring. Additionally, the company offers truSculpt, a high-powered RF system for non-invasive fat reduction and skin tightening, as well as Enlighten SR/III, a dual-wavelength laser platform for tattoo removal and pigmented lesion treatment. Cutera also provides Excel HR for permanent hair reduction and xeo, a multi-application platform for hair removal, vascular lesion treatment, and skin rejuvenation. Its products are distributed through a combination of direct sales, international distributors, and service networks.
On March 5, 2025, Cutera, Inc. filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas, signaling significant financial restructuring efforts. The company, founded in 1998 and headquartered in Brisbane, California, has faced challenges in maintaining profitability despite its innovative product offerings. Its financial struggles are reflected in its current market capitalization of $1.99M and a price-to-sales ratio of 0.01, indicating poor revenue generation relative to its market value. The companys stock price has declined sharply, trading at $0.11 as of the latest data, with key moving averages (SMA20: 0.34, SMA50: 0.40, SMA200: 0.82) all above the current price, suggesting bearish momentum. The average true range (ATR) of 0.06 highlights moderate volatility in recent trading sessions.
Additional Sources for CUTR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CUTR Stock Overview
Market Cap in USD | 2m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2004-03-31 |
CUTR Stock Ratings
Growth 5y | -85.5% |
Fundamental | -57.0% |
Dividend | 0.0% |
Rel. Strength Industry | -95.1 |
Analysts | 3.67/5 |
Fair Price Momentum | 0.07 USD |
Fair Price DCF | - |
CUTR Dividends
No Dividends PaidCUTR Growth Ratios
Growth Correlation 3m | -1.4% |
Growth Correlation 12m | -91.6% |
Growth Correlation 5y | -56.1% |
CAGR 5y | -62.62% |
CAGR/Max DD 5y | -0.63 |
Sharpe Ratio 12m | -1.16 |
Alpha | -106.86 |
Beta | 1.85 |
Volatility | 268.39% |
Current Volume | 29608.6k |
Average Volume 20d | 221.8k |
As of March 14, 2025, the stock is trading at USD 0.10 with a total of 29,608,605 shares traded.
Over the past week, the price has changed by -17.04%, over one month by -76.85%, over three months by -73.02% and over the past year by -95.11%.
No, based on ValueRay Fundamental Analyses, Cutera (NASDAQ:CUTR) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -56.96 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CUTR as of March 2025 is 0.07. This means that CUTR is currently overvalued and has a potential downside of -30%.
Cutera has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold CUTR.
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CUTR Cutera will be worth about 0.1 in March 2026. The stock is currently trading at 0.10. This means that the stock has a potential downside of -20%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 2 | 1900% |
Analysts Target Price | 2 | 1900% |
ValueRay Target Price | 0.1 | -20% |